Overview

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

Status:
Recruiting

Trial end date:
2022-08-01

Target enrollment:

Participant gender:

Summary

MARIO-3 is a Phase 2 multi-arm combination cohort study designed to evaluate IPI-549, Infinity Pharmaceutical's first-in-class, oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC) and in combination with Tecentriq and Avastin (bevacizumab) in front-line renal cell cancer (RCC).

Phase:

Phase 2

Details

Lead Sponsor:

Infinity Pharmaceuticals, Inc.

Collaborator:

Roche Pharma AG

Treatments:

Albumin-Bound Paclitaxel
Atezolizumab
Bevacizumab
Paclitaxel